Q4FY21 Result Update - Glenmark Pharmaceuticals - ICICI Direct

Q4 revenues grew 3.3% YoY to Rs. 2860 crore. Domestic sales grew 7.7% YoY to Rs. 824 crore. US sales grew 5.2% to Rs. 801 crore led by new launches. Europe business grew 2.6% YoY to Rs. 422 crore amid enhanced lockdown measures. RoW markets de-grew 0.7% YoY to Rs. 334 crore whereas API segment grew 26.7% YoY to Rs. 331 crore. LatAm market de-grew 26.6% YoY to Rs. 130 crore due to a challenging environment amid the pandemic. EBITDA margins improved 148 bps YoY to 18.3% mainly due to better gross margins partly offset by higher other expenditure. EBITDA grew 12.4% YoY to Rs. 523 crore. Adjusted PAT grew ~25% YoY to Rs. 234 crore.

For details, click on the link below: Link to the report

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.594.65 as compared to the previous close of Rs. 592.6. The total number of shares traded during the day was 178986 in over 5798 trades.

The stock hit an intraday high of Rs. 611.6 and intraday low of 591.55. The net turnover during the day was Rs. 107186721.

Source : Equity Bulls

Keywords